Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Investing Activities: 2015-2024

Historic Cash from Investing Activities for Viking Therapeutics (VKTX) over the last 10 years, with Dec 2024 value amounting to -$553.4 million.

  • Viking Therapeutics' Cash from Investing Activities rose 517.83% to $160.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.4 million, marking a year-over-year increase of 151.96%. This contributed to the annual value of -$553.4 million for FY2024, which is 208.99% down from last year.
  • Viking Therapeutics' Cash from Investing Activities amounted to -$553.4 million in FY2024, which was down 208.99% from -$179.1 million recorded in FY2023.
  • Viking Therapeutics' 5-year Cash from Investing Activities high stood at $54.8 million for FY2022, and its period low was -$553.4 million during FY2024.
  • In the last 3 years, Viking Therapeutics' Cash from Investing Activities had a median value of -$179.1 million in 2023 and averaged -$225.9 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 456.97% in 2020, then plummeted by 427.08% in 2023.
  • Viking Therapeutics' Cash from Investing Activities (Yearly) stood at $41.6 million in 2020, then fell by 8.68% to $38.0 million in 2021, then surged by 44.24% to $54.8 million in 2022, then tumbled by 427.08% to -$179.1 million in 2023, then tumbled by 208.99% to -$553.4 million in 2024.